MTOR and pancreatic adenocarcinoma: The treatments of the human triple-negative mammary carcinoma cell line HCC70 with the PI3K/mTOR inhibitor PI-103 (prediction score of 0.74, Figure 3A), and the pancreatic adenocarcinoma epithelial cell line Panc 04.03 with the Src inhibitor PP1 (prediction score of 0.91, Figure 3B) are clearly effective regardless of the initial cell densities.